Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2011 Results
Date:3/27/2012

010. The 2010 royalty was reported to the company and recorded in the first quarter of 2011.

Total operating expenses decreased in the fourth quarter of 2011 to $3.9 million from $4.5 million in the same period a year ago. Operating expenses in the fourth quarter of 2011 included $314,000 in non-cash stock-based compensation, as compared to $1.6 million in the same year-ago quarter. Total operating expenses increased in 2011 to $19.4 million from $15.7 million in 2010. Operating expenses in 2011 included $3.3 million in non-cash stock-based compensation, as compared to $4.9 million in 2010. The annual increase was due primarily to increased average headcount in sales and marketing and related costs, higher clinical trial and collaboration costs for the ongoing development of the company's ovarian cancer program and VASCLIR®, as well as an increase in legal fees including those associated with the company's MAS litigation. Research and development expenses for 2011 also included $435,000 for the Correlogic asset acquisition.

Net loss for the fourth quarter was $3.1 million or $(0.21) per share, as compared to $4.0 million or $(0.38) per share in the same year-ago quarter. Net loss for 2010 included $8.6 million in reorganization items and $4.4 million in gains resulting from the exercise and fair value revaluation of common stock warrants. Net loss for 2011 was $17.8 million or $(1.25) per share, as compared to $19.0 million or $(1.83) per share in 2010.

As of December 31, 2011, the company's cash and cash equivalents totaled $22.5 million. The company used $5.0 million in cash from operations during the fourth quarter, including $435,000 for the Correlogic asset acquisition.

Management Commentary"2011 showed substantial expansion in OVA1 tests usage leading to another year of revenue growth for Vermillion," said Gail S. Page, the company's president and chief executive officer. "In fact, more than 3,700 or 11% of the nation's gyne
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
3. Vermillion Reports Results for the Second Quarter 2011
4. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
5. Vermillion Announces Joining Russell Microcap® Index
6. Vermillion Announces Notice of Allowance for Alzheimer Patent
7. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
8. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
9. Stephens Initiates Coverage on Vermillion
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Vermillion Announces Issuance of European Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... VANCOUVER , June 30 /PRNewswire/ - Sirius Genomics, ... has been appointed Senior Director of Business Development. , ... "Sirius Genomics is on ... Kam,s extensive background in partnering with both global pharmaceutical and medical ...
... Tekscan, Inc. ... the traditional pin connection, Tekscan is now offering a lower-cost termination method to enable OEM ... , ... -- Tekscan, Inc. announces a new lower-cost connection option for its custom FlexiForce® sensors ...
... A ... users sports performance , ... Denmark (PRWEB) June 30, 2010 -- Recent researches have found scientific evidence that proves ... researchers from Denmark revealed that the level of enhancement of performance due to the use ...
Cached Biology Technology:Sirius Genomics Announces Appointment of Senior Director of Business Development 2Lower-Cost ZIF and LIF-Compatible Connection Option for Tekscan Custom Force Sensors 2Recent Study Reports Reveals that HGH May Aid Performance 2
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... , July 30, 2014 The Nano-Bio ... United States Air Force Research Laboratory (AFRL), has ... Binghamton University to develop electronics ... (HPM). The $425,000 project, with contributions from the ... i3 Electronics, Inc. ( Endicott, N.Y. ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... Mixing commonly used antibiotics with common blood ... pressure) and induce shock in older patients, requiring ... CMAJ ( Canadian Medical Association Journal ) ... antibiotics (erythromycin, clarithromycin and azithromycin) are among the ...
... Company part owned by Shell has announced plans ... of the Western North Pacific gray whale population. ... population exist today, and their primary feeding habitat off ... besieged by multiple oil and gas exploration and development projects. ...
... January 16, 2011 (BRONX, NY) In ... gene expression influences human disease, scientists at Albert ... for the first time ever successfully visualized single molecules ... cells. The scientific achievement is detailed in the January ...
Cached Biology News:Oil giant plans new platform near feeding ground of critically endangered whale 2Oil giant plans new platform near feeding ground of critically endangered whale 3
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Request Info...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: